Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
1.310
+0.040 (3.15%)
At close: Feb 21, 2025, 4:00 PM
1.271
-0.039 (-3.00%)
After-hours: Feb 21, 2025, 4:41 PM EST
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Regulus Therapeutics stock have an average target of 10.33, with a low estimate of 3.00 and a high estimate of 28. The average target predicts an increase of 688.55% from the current stock price of 1.31.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
The average analyst rating for Regulus Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +663.36% | Nov 11, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +663.36% | Oct 30, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +663.36% | Oct 8, 2024 |
Oppenheimer | Oppenheimer | Buy Reiterates $7 | Buy | Reiterates | $7 | +434.35% | Aug 14, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +663.36% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.87
from -1.58
EPS Next Year
-1.26
from -0.87
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | n/a | |||
Avg | n/a | n/a | n/a | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -0.81 | -0.98 | -0.95 | |||
Avg | -0.87 | -1.26 | -1.79 | |||
Low | -0.89 | -2.21 | -2.77 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.